Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03575780 · ClinicalTrials.gov registry record · Phase 1
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
A Phase 1 study, sponsored by Athenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03575780 is a Phase 1 study that has completed, run by Athenex. The registered enrollment target is 18 participants.
The verdict
NCT03575780, a Phase 1 study, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis lesions on the face or balding scalp.
Interventions
- DRUG KX2-391 Ointment 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03575780
The ClinicalTrials.gov registry entry for NCT03575780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Athenex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KX2-391 Ointment 1% is the first listed.
NCT03575780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03575780 about?
NCT03575780 is a clinical study titled "Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis". This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis lesions on the face or balding scalp.
What is the current status of trial NCT03575780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-09-07. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT03575780?
The interventions under investigation include: KX2-391 Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT03575780?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.